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The graft-versus-leukemia (GVL) effect is thought to be responsible for the significantly reduced relapse rates following allogeneic stem cell transplantation for hematological malignancies compared with autologous transplantation or chemotherapy. However, this therapeutic benefit is offset by higher transplant-related mortality (TRM), due mainly to the harmful effects of the preparative regimen, graft-versus-host disease (GVHD) and defective recovery of donor immunity. For years, clinical investigators have struggled with the conflicting requirements of controlling leukemia while preventing GVHD. In order to better regulate the outcome after peripheral blood stem cell transplantation (PBSCT) and to determine critical factors biasing towards GVHD or GVL, we have studied the effect of independently controlling hematopoietic recovery, by means of adjusting CD34 cell dose, and immune recovery, by T-cell depletion (TCD) followed by timed and dosed addition of T cells after transplant.
These studies have been facilitated by advances in stem cell transplantation and TCD techniques. We have used positive CD34 cell selection followed by negative T-cell selection to achieve approximately five logs of TCD. Since it was uncertain whether TCD alone could prevent GVHD, we have traditionally used cyclosporine (CSA) posttransplant as additional GVHD prophylaxis. Results from our clinical trials and others indicate that doses of CD34 cells above 3 Â 10 6 /kg optimize post-transplant outcome. To reach this stem cell dose target, we use G-CSFmobilized peripheral blood as the stem cell source. Following TCD PBSCT, patients without grade II or greater acute GVHD (aGVHD) were eligible to receive two donor lymphocyte infusions (DLIs) on days +45 and +100 in order to enhance the GVL effect and promote immune reconstitution, while benefiting from the potential mitigating effect of delayed lymphocyte infusions on GVHD severity.
1,2 The final T-cell dose after the DLIs (6 Â 10 7 /kg) was chosen as a level comparable to that of an unmanipulated bone marrow transplant. It was hoped in this way to reduce the high incidence of chronic GVHD (cGVHD) occurring after the 10-fold larger T-cell doses given in a PBSCT. 3 Using this strategy, we have demonstrated a relatively low TRM (6% at day +100 and 16% at day +200) and risk of a GVHD (12 and 39%, before and after DLI, respectively). Severe a GVHD (grades III-IV) occurred in only 8% of the patients, and there was no mortality because of GVHD or its consequences. Diseasefree survival (DFS) was significantly higher in standard-vs high-risk patients (75 vs 22%), secondary to a higher risk of relapse in the latter group (12 vs 66%). 2 CSA immunosuppression was used throughout the development of these TCD and delayed lymphocyte infusion protocols. While it seemed prudent to use CSA after DLI, it was not clear whether there was a requirement for CSA immediately after the TCD transplant. Clinical results indicate that CSA may not be required for GVHD prevention after intensive TCD of bone marrow allografts. 4, 5 However, there are no substantial data to indicate whether CSA is necessary to prevent GVHD after TCD PBSCT. It is important to determine whether CSA is required, as the unnecessary addition of further immunosuppression could compound the prolonged immunodeficiency seen after TCD transplants and increase TRM and relapse. CSA can impair the GVL response: we have seen both remissions of persisting leukemia after stopping CSA, as well as relapses occurring shortly after initiation of GVHD treatment. Data from T-cell-replete transplants suggest that relapse rates can be significantly reduced by simply lowering the CSA dose in the immediate posttransplant period. [6] [7] [8] To find the threshold dose of T cells required to prevent GVHD and determine the place of post-transplant immunosuppression after TCD PBSCT we, therefore, studied the effect of CSA in the early post-transplant period. We compared three successive cohorts of patients: one receiving SD CSA, one receiving LD CSA, and one receiving no immunosuppression. In the absence of CSA, we observed an increase in the incidence and severity of aGVHD.
Patients and methods

Patients
Between March 1999 and August 2001, 82 consecutive patients with hematologic malignancies and an HLAidentical sibling donor were treated under National Institutes of Health protocols, 97-H-0099 and 99-H-0046, approved by the National Heart, Lung, and Blood Institute (NHLBI) Institutional Review Board. Stopping rules for the development of aGVHD determined the number of patients enrolled in each successive cohort: group 1 -standard dose (SD) CSA, group 2 -low dose (LD) CSA, and group 3 -no CSA. At each stage, the study was designed to stop if aGVHD (grade XII) occurred before day +45 in (1) two or fewer patients in the first 20, or (2) six or more patients at any point during patient accrual. Accordingly, 36 patients receiving SD CSA, 20 patients receiving LD CSA, and 26 patients receiving no CSA posttransplant were accrued. A comparison of the three cohorts can be found in Table 1 .
Preparative Regimen
All patients received a conditioning regimen of fractionated TBI, 13.6 Gy. in eight fractions over 4 days, followed by cyclophosphamide, 120 mg/kg over 2 days.
Lymphocyte and stem cell collection
Lymphocytes and stem cells were collected from the donor by separate apheresis procedures, using a CS3000 Plus automated blood cell separator (Baxter Healthcare, Deerfield, IL, USA). Prior to stem cell mobilization, mononuclear cells were collected by leukapheresis and cryopreserved in aliquots for future DLIs. Donors then received G-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA), 10 mg/kg/day subcutaneously for 6 days. On days 5 and 6, 15 l volume of leukaphereses were performed using the CS3000 Plus to obtain PBSCs. Prophylactic calcium chloride infusions were routinely administered to avoid citrate toxicity. The target CD34 dose after TCD was 43 Â 10 6 /kg. TCD CD34 selection and TCD was performed by one of two selection methods. In the first cohort of patients (protocol 97-H-0099), the Ceprate selection system (CellPro, Bothell, WA, USA), based on biotin-avidin immunoadsorbtion, was utilized. This process included an initial CD34-positive selection on the Ceprate SC column, followed by a CD2-negative selection on a second column. In the second and third cohorts of patients (protocol 99-H-0046), TCD was accomplished with the Isolex 300i immunomagnetic cell selection system (Nexell Therapeutics, Irvine, CA, USA), using the program for simultaneous positive and negative selection. On the Isolex system, we used the manufacturer's antibody for positive selection of CD34+ cells and a cocktail of three T-cell-specific monoclonal antibodies (CD2, CD6, CD7) for negative selection of T cells. In these latter two cohorts, the final T-cell dose of the allograft was fixed at 5 Â 10 4 CD3+ cells/kg, requiring supplementation of the final product with T cells from the original unmanipulated PBSC component. TCD PBSCT products were either infused into patients immediately or cryopreserved in a control rate freezer and stored in liquid nitrogen for subsequent thawing and infusion.
Immunosuppression and monitoring of CSA levels
As additional GVHD prophylaxis, the first cohort of patients (n ¼ 36) received SD CSA (target plasma level 200-400 mg/ml) and the second patient cohort (n ¼ 20) received LD CSA (target plasma level 100-200 mg/ml), starting i.v. on day À4 until an oral dose was tolerated. The third cohort (n ¼ 26) received no CSA during the first 6 weeks following the transplant. On day +44, all patients were started on CSA (target plasma level 200-400 mg/ml), which was continued until at least day +130 or longer if cGVHD occurred.
Donor lymphocyte infusions
To prevent relapse and confer donor immune function, patients received planned infusions of cryopreserved donor peripheral blood mononuclear cells on days +45 and +100, at a T-cell dose of 1 Â 10 7 and 5 Â 10 7 CD3+ cells/ kg, respectively. Patients developing grade II or greater aGVHD after transplant were excluded from DLI if GVHD was still active and requiring corticosteroid treatment. Patients with chronic myelogenous leukemia (CML) in chronic phase in cytogenetic remission on day +100, and therefore at low risk for relapse, were excluded from the day +100 DLI.
Post-transplant management
All patients received fluconazole for antifungal prophylaxis, weekly trimethoprim/sulfamethoxazole for pneumocystis prophylaxis, and acyclovir for antiviral prophylaxis. Blood was tested weekly for cytomegalovirus pp65 antigen until day +100, and ganciclovir with high-dose immunoglobulin was initiated when there was evidence of CMV reactivation. aGVHD was treated with methylprednisolone (1 mg/kg/day-1.0 gm/day), tapered according to response. cGVHD was treated with prednisone (10-30 mg/day) and CSA daily or on alternate days. The diagnosis and grading of aGVHD and cGVHD were established according to the Seattle criteria. 9 
Statistical analysis
Differences in transplant outcomes between treatment groups were compared using Fisher's exact test. Probabilities of TRM, relapse, and survival were calculated according to the method of Kaplan and Meier. 10 
Results
Patients
A total of 82 patients between 10 and 56 years old (median 37 years) were enrolled, 49 males and 33 females.. In all, 36 patients had CML, of whom 28 were in chronic phase and eight were in accelerated phase/blast crisis; 21 patients had acute myelogenous leukemia, seven in first remission, six in second or subsequent remission, and eight in relapse or with refractory disease. A total of 12 patients had myelodysplastic syndrome. Seven patients had acute lymphoblastic leukemia: one in first remission, four in second or subsequent remission, and two in relapse or with refractory disease. Four patients had chemorefractory, bulky chronic lymphocytic leukemia or non-Hodgkin's lymphoma, and two patients had multiple myeloma. In total, 43 patients were designated as standard risk for transplant complications and relapse; the remaining 39 patients were considered high risk.
The three patient cohorts were similar with regard to age, sex, seropositivity for CMV, and donor-recipient sex disparity. Allografts in the SD CSA group contained a lower median CD34 dose and higher CD3 dose than the other two groups, related to differences in the cell selection systems. Patients receiving SD and LD CSA had a longer median follow-up time than patients not receiving CSA (1415 and 991 days vs 414 days). There was also a trend towards more high-risk disease in patients receiving LD CSA, compared with patients not receiving CSA. An intergroup comparison of patient characteristics is shown in Table 1 .
Hematologic recovery and engraftment
All patients reached an absolute neutrophil count (ANC) of 500 neutrophils/ml. The median day to achieve an ANC4500/ml was 11 (range 9-13). The median day to achieve an untransfused platelet count of 420 000/ml was 11 (range 9-14). There were no differences between the groups in the median day to reach ANC4500/ml, ANC41000/ml, platelet count 420 000/ml, or platelet count 450 000/ml. Two patients from the 'no CSA' group developed graft failure on days +21 and +23, requiring second transplants. One patient from the SD CSA cohort developed late graft failure and died on day +220.
DLIs
The day +45 DLI was given to all engrafted and surviving patients without active aGVHD (grades II-IV), at a dose of 1 Â 10 7 CD3+ cells/kg. In patients receiving CSA posttransplant (LD+SD groups), 50 patients (89%) received the day +45 DLI. Six did not receive it because of early death in two, untreatable relapse in one, regimen-related toxicity in one, and grade II aGVHD in two. In the 'no Table 1 Clinical characteristics of the transplant recipients CSA' group, only 19 patients (65%) received the day +45 DLI. Nine patients did not receive it because of grades II-IV aGVHD in six patients, early graft failure in two, requiring second transplants, and regimen-related pulmonary toxicity in one patient. Eight patients (30.7%) in the 'no CSA' cohort did not receive any DLI compared with four patients (7.1%) receiving SD or LD CSA (P ¼ 0.01) (Figure 1b ).
aGVHD and cGVHD
In spite of the low T-cell doses (median 1 Â 10 5 CD3+ cells/kg in the first cohort and a fixed CD3 dose of 5 Â 10 4 / kg in the subsequent two cohorts), aGVHD did occur prior to DLI on day +45. Of the 55 patients receiving CSA, five patients (14%) in the SD CSA group and two patients (10%) in the LD group developed aGVHD prior to DLI (grade II only). Of the patients not receiving posttransplant CSA, eight (33.3%) developed moderate-tosevere aGVHD prior to DLI (grade II (4), grade III (3), grade IV (1)) (Table 2 and Figure 1a ). There were no significant differences in overall rates of aGVHD between the groups, as patients receiving CSA developed more aGVHD after DLI on day +45 (Figure 1 ). The cumulative probability of grades II-IV aGVHD and cGVHD for all patients was 38 and 53%, respectively. There was a nonsignificant trend towards increased cGVHD in patients not receiving CSA, when compared to a cohort of LD CSA and SD CSA patients receiving below the median T-cell dose of 1 Â 10 5 CD3+ cells/kg (Table 2 ). In the SD CSA group, cGVHD varied significantly with the T-cell dose, as we have previously shown. 
Discussion
Until recently, little attention has been given to the relationship between the cellular content of the graft and the outcome after allogeneic SCT. In attempting to understand the relative roles of stem cell and lymphocyte doses on transplant outcome, it is necessary to perform transplants using defined doses of CD34 and CD3 cells. (a) The probability of Xgrade II and Xgrade III aGVHD before the day 45 DLI was significantly higher in patients not receiving post-transplant CSA. The overall incidence of aGVHD was similar in both groups, as patients receiving CSA were more likely to receive their planned DLIs (b) and subsequently develop GVHD. Such studies have been greatly facilitated by the use of antibody-based automated cell-selection systems to select positively CD34+ cells and deplete T cells. Using the positive/negative selection approach, we have previously defined stem cell doses of at least 3 Â 10 6 CD34 cells/kg as optimum for DFS following HLA-matched TCD PBSCT. In these protocols, using standard doses of CSA posttransplant and planned DLIs, we achieved durable engraftment in 97% of patients and encountered no mortality because of aGVHD or cGVHD. 2 In this study, we set out to determine whether posttransplant immunosuppression was necessary for GVHD prevention in the context of rigorous TCD. Based on the results of several clinical trials demonstrating reduced relapse risk and improved outcomes when lower doses of CSA was used early post-transplant, [6] [7] [8] we argued that the elimination of CSA in the first 6 weeks post-transplant would result in more rapid immune recovery and a potentiation of GVL reactivity. After a standard TBI/ cyclophosphamide preparative regimen, patients received a G-CSF-mobilized PBSC allograft engineered to deliver a high-stem cell dose and a low T-cell dose (median 1 Â 10 5 CD3+ cells/kg in the first cohort and a fixed CD3 dose of 5 Â 10 4 /kg in the subsequent two cohorts). This made possible a rigorous comparison of early post-transplant GVHD (before the addition of donor lymphocytes on day +45) between patient cohorts receiving SD or LD CSA and a group receiving no CSA. We found that LD CSA was as effective as SD CSA in preventing GVHD before the day +45 DLI. However, grades II-IV early aGVHD was significantly more frequent and more severe in patients receiving no CSA (33.3 vs 12.7%, P ¼ 0.04, including the only four grades III-IV cases in the 'no CSA' group). Thus, a T-cell dose of 5 x10 4 CD3 cells/kg is apparently not low enough to prevent GVHD following PBSCT without additional CSA.
As follow-up was short and the relapse risks differed between the LD CSA and no CSA groups, it was not possible to determine whether the absence of CSA early postgraft had a favorable impact on leukemic relapse. Furthermore, the delayed lymphocyte infusions in this protocol may have lessened the differences in outcome based upon early events post-transplant. Thus, although aGVHD was more common in the first 6 weeks posttransplant in the no CSA group, the final incidence of aGVHD was comparable between the groups because of the impact of the DLIs on the subsequent occurrence of GVHD. This analysis therefore focused on the differences in transplant outcome in the first 6 weeks post-transplant.
There is clearly a strong relation between the T-cell content of the allograft and the risk of both GVHD and graft failure. Successful prevention of GVHD has been reported in bone marrow transplantation using sheep red cell rosetting to produce a 4-5-log reduction in T-cell dose. In the setting of HLA-identical transplantation, most studies indicate a threshold T-cell dose of approximately 10 5 CD3+ cells/kg for GVHD prevention. 11, 12 The increased risk of graft failure seen at these low T-cell doses can be offset by intensification of the preparative regimen. 13, 14 At least two studies have demonstrated that ex vivo TCD of a bone marrow allograft, with T-cell-directed monoclonal antibodies and complement, can produce reliable engraftment (495%) and low rates of aGVHD (B20% grades II-IV), in the absence of post-transplant immunosuppression. 4, 5 Our study suggests that in the setting of a G-CSF-mobilized PBSCT, TCD may not be as effective in preventing GVHD when post-transplant immunosuppression is omitted. The CD3 dose selected in this study was based upon the complete protection from GVHD observed with less than 5 Â 10 4 CD3+ cells/kg in HLA-mismatched transplants. 15 A recent small study of TCD PBSCT demonstrated that even lower T-cell doses, on the order of 1 Â 10 4 CD3+ cells/kg, may not completely abrogate aGVHD. 16 However, it is difficult to evaluate the precise relation of the T-cell dose with GVHD and graft failure, because available transplant data concern diverse approaches to TCD, variable T-cell doses, and often describe preparative regimens containing antilymphocyte antibodies, which produce prolonged post-transplant immunosuppression.
Although TCD can substantially reduce the incidence and severity of aGVHD and cGVHD, this benefit can be outweighed by a concomitant delayed immune recovery, leading to increased rates of graft rejection, disease relapse, and post-transplant infection. As a consequence, studies comparing TCD PBSCT with unmanipulated PBSCT have failed to show an advantage for TCD. 17 The full potential of TCD PBSCT is unlikely to be realized unless it permits the compensatory benefit of withdrawing postgraft immunosuppression. Our findings are important because they indicate that, if TCD PBSCT is to be optimally exploited, it will be necessary to further reduce the T-cell dose if immunosuppressive agents are to be avoided posttransplant. In a future study, we aim to reduce the risk of graft failure by intensifying the immunosuppressive effect of the preparative regimen using fludarabine, while reducing the risk of GVHD by further lowering the T-cell dose. Despite the current limitations of TCD, we see the establishment of a GVHD-free, immunosuppression-free PBSCT as a necessary platform for the evaluation and optimization of transplant approaches using selectively depleted T-cells (to prevent GVHD) 18 and specific adoptive immunotherapy or targeted vaccination strategies to enhance GVL.
